Studies show that the pro-tumor effect of IL-17 supporting tumor angiogenesis increases in the chronic phase of cancer and inflammation development, and dominates over anti-cancer effects, promoting the expansion of cytotoxic T lymphocytes and other immune cells fighting cancer [45,46]. This evidence concerns the gene IL17A and neoplasm.